🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🚀 New in Journal of Clinical Oncology - ROBOMET shorturl.at/NawNo! SABR vs standard #radiotherapy for painful bone mets. ✅ Pain relief at 1 month: 🔹 SABR (20 Gy single dose): 37% complete response 🔸 versus (8 Gy): 25% complete response ⚡ at 3-months ⬆️ withSABR: 54% vs 31%, p= .048

🚀🔥⚡️ Excited to announce #URONCOR2025! A top-tier symposium on radiotherapy in GU cancers. Welcoming international experts Vérane Achard & Filippo Alongi ! Register today: uroncor.seor.es #GUoncology #RadiationOncology #ProstateCancer #SEOR

New insights on SBRT in recurrent ovarian cancer – now in CTRO: “SBRT in recurrent oligometastatic ovarian cancer: An EORTC Y-ECI GCG systematic review” 👉 doi.org/10.1016/j.ctro… 🎯 Local control ⏳ Delayed systemic therapy ⚖️ Personalized strategy EORTC

Join us in Lisbon early December for a wonderful meeting how to apply data in clinic across GU cancers! Mirrors of Medicine Prof Ananya💙 @achoud72.bsky.social Badrinath Konety, MD, MBA Paul Sargos silke gillessen Marc-Olivier Timsit, MD, PhD 🎗️ Pedro C Barata, MD MSc FACP Marinos Tsiatas ANASTASIOS KYRIAZOGLOU Myrto K. Moutafi Bernadett Szabados Manuela Schmidinger OncoAlert Daniele Raggi

Is RT and ADT Good Enough in PSMA-Staged High-Risk Prostate Cancer? - Priyamvada Maitre (Priyamvada Maitre) Vedang Murthy oncodaily.com/insight/priyam… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #ProstateCancer #RT #ADT #PSMA CancerWorld

🔥This Thursday I’ll moderate the Bladder Cancer session at #URONCOR2025 👥 🔹 Vérane Achard : RT in NMIBC 🔹 Enrique Maldonado: Trimodal therapy 🔹 Félix Guerrero-Ramos : Bladder preservation 🕕 18:15 | 📍 Main Hall Join us! #Oncology #SEOR #BladderCancer

Thank you for the warm welcome Felipe Couñago PhD . It was truly a pleasure to visit the GenesisCare España centers in Madrid. I was deeply impressed by the outstanding quality of the work and, above all, the motivation and dedication of the team — a true example of excellence in oncology 🌟

Many thanks to my dear friend Felipe Couñago PhD for the kind invitation to visit GenesisCare España radiation oncology realities in Madrid: I breathed an exciting atmosphere of enthusiasm, passionate motivation, excellent management and high sensitivity for cancer care

🙌 Honored to be part of this great session at #URONCOR2025 in beautiful Madrid 🇪🇸! 🙏 Thanks for the kind words and very nice moderation! #BladderCancer #Radiotherapy #TeamWork 💬🧠

Well said. Clear expectations, regular check-ins, and adapting to our team’s strengths are performance multipliers. Align. Assess. Adjust. Repeat.

How to optimize treatment for patients with non-muscle-invasive bladder cancer (NMIBC): Morgan Roupret Vérane Achard Félix Guerrero-Ramos - Intensification with systemic immunotherapy in addition to BCG in BCG-naïve patients? What can we learn from CREST and ALBAN trials?

Join us at the RENALC-BLADDR-PROSCA 2025 hybrid global forum on GU Oncology this December in Lisbon! Dive into the latest evidence with top experts using the Mirrors of Medicine™ case-based approach. 🐦Early bird registration is now open!➡️ Register now: gu-global-forum.org/registration-2…

Thanks Sophia Kamran, MD & Constantinos Zamboglou for this invitation to highlight keypoints and thoughts about ADT and Post-op RT. sciencedirect.com/science/articl… ✨✨✨✨✨✨✨✨✨✨

Why attend #RENALC25, #BLADDR25 and #PROSCA25? Hear it straight from Vérane Achard in this quick video 👇 ➡️ Register now: tinyurl.com/mryx8kwe 💎Dive into the clinical application of new GU oncology data 👥 Learn from multidisciplinary experts 🗓️3-6 December 2025 | 📍

How to manage gynecomastia with ARPIs monotherapy? A review by @nassimVibert 🙏 sciencedirect.com/science/articl… #ProstateCancer #Prostate #life

Honored to be co–first author with Huck constance on this paper challenging dogma. Next : #BRACEClinicalTrial, which I co-lead with Piet Dirix, opening soon in BE🇧🇪 thanks to #komOpTegenKanker and EORTC . We aim to explore the role of RT in BCG-unresponsive CIS. Stay tuned!

Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GÖTEBORG-1 Trial sciencedirect.com/science/articl… This long-term follow-up study from the GÖTEBORG-1 screening trial evaluated outcomes in 488 men with

Jb Beauval Pignot Géraldine Ploussard Guillaume Pouessel Damien Roubaud Guilhem @MRoumiguie Paul Sargos Morgan Roupret Vérane Achard Félix Guerrero-Ramos joaquim bellmunt Enrique Grande Benjamin Pradere Gautier Marcq tombal Riccardo Campi Thomas Zilli

🇫🇷🇧🇪Ouverture des JER du GETUG avec le débat sur la prise en charge des mCRPC. ✨ Roubaud Guilhem tombal Helissey carole Bernard-Tessier

🌟Challenges in Defining Clinical CR to Systemic Therapy in MIBC🌟 EORTC #STARBURST project 🖋️ Alexandra Masson-Lecomte @AFUrology, Guillaume Grisay, Julien Van Damme,  Vérane Achard  , Laura S. Mertens, Robert Huddart💙, francesco soria, Lars Dyrskjøt, Yves Allory Institut Curie,